Kimberly Clark AI Stock Analysis
Kimberly Clark (KMY) AI Stock Analysis
Kimberly Clark
(XETRA:KMY)
No summary available
Kimberly Clark (KMY) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 36.39B
- Dividend Yield
- 4.43%
- Average Volume (3M)
- 883
- Price to Earnings (P/E)
- 11.0
- Beta (1Y)
- 0.22
- Revenue Growth
- -13.28%
- EPS Growth
- 59.26%
- Country
- Germany
- Employees
- 36,000
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Kimberly Clark Business Overview & Revenue Model
Company Description
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care. The North America segment offers disposable...
Kimberly Clark Earnings Call Summary
The call was broadly optimistic, led by the completed Kenvue acquisition, strong confidence in the integration plan, on-track cost synergies, positive Kenvue brand momentum, North American tissue strength, continued productivity, and sustained investment in future growth. Offsetting challenges included North American execution and distribution issues, China diaper recovery, Kenvue skincare and oral-care weakness, elevated freight-driven inflation, and expected mid-single-digit EPS dilution in 2027. Overall, the highlights significantly outweigh the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company maintained fiscal 2026 guidance, expecting stronger underlying business momentum, a strong global commercial agenda for the fourth quarter, incremental cost mitigating actions, and an easier comp in the fourth quarter; full-year gross inflationary impacts are projected at around $250 million, including $50 million in the second quarter and around $200 million in the second half, while gross productivity was 6.1% year to date and 5.8% for the third quarter. Pricing is expected to be relatively flat for the year, versus year-to-date pricing down about 70 basis points for the total company and 80 basis points in North America. For 2027, adjusted EPS dilution is expected to be mid-single-digit versus standalone Kimberly-Clark EPS, with amortization of intangible assets included in non-GAAP metrics, followed in 2028 by mid to high single-digit EPS growth on a compounded basis, two years versus the baseline of 2026 standalone KC; the company also expects approximately getting to about a two times leverage by the end of the second year of the transaction. Cost synergies are about $1.9 billion, with overheads optimization driving about a third, COGS closer to 40% of the overall, give or take, so between 30%-40% of the synergies, and sales and marketing and trade spend optimization comprising the third bucket; revenue synergies were $1.4 billion in revenue, $200 million in EBIT contribution net, and reinvestment of around $300 million, or close to 60% in the modeling.
Kimberly Clark Risk Analysis
Kimberly Clark disclosed 26 risk factors in its most recent earnings report. Kimberly Clark reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksKimberly Clark Peers Comparison
Overall Rating
CHD78Outperform
PG72Outperform
CL67Neutral
UL64Neutral
CLX58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $26.67B | 34.66 | 18.21% | 1.09% | 1.70% | 2.07% | |
| 72Outperform | $393.56B | 25.16 | 29.55% | 2.55% | 3.52% | -3.74% | |
| 67Neutral | $79.23B | 38.72 | 1135.82% | 2.12% | 5.91% | -28.30% | |
| 64Neutral | $141.99B | 14.07 | 58.26% | 3.25% | -17.45% | 8.84% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 58Neutral | $13.26B | 19.69 | -1920.57% | 4.55% | 6.28% | -13.15% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:KMY | Kimberly Clark | 99.15 | 13.48 | 15.73% | |
| CHD | Church & Dwight Company | 113.00 | 30.98 | 37.77% | |
| CLX | Clorox Company | 109.46 | 13.14 | 13.65% | |
| CL | Colgate-palmolive Company | 99.67 | 22.71 | 29.50% | |
| PG | Procter & Gamble Company | 169.80 | 28.09 | 19.82% | |
| UL | Unilever plc | 66.21 | 4.85 | 7.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
